Publications from the Centre for Immuno-Oncology
Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer.
Javed SR. et al, (2024), British journal of cancer
NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302)
Coveler A. et al, (2022), ANNALS OF ONCOLOGY, 33, S697 - S698
NUC-7738 in patients with advanced solid tumours: Phase I results from the NuTide:701 phase I/II study
Symeonides SN. et al, (2022), ANNALS OF ONCOLOGY, 33, S745 - S746
PHASE 1 STUDY OF THE PORCUPINE (PORCN) INHIBITOR RXC004 IN COMBINATION WITH THE PD-1 INHIBITOR NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
Cook N. et al, (2022), JOURNAL FOR IMMUNOTHERAPY OF CANCER, 10, A752 - A752
Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic.
Skolariki A. et al, (2022), Exploration of targeted anti-tumor therapy, 3, 172 - 199
The evolving role of PARP inhibitors in advanced ovarian cancer
Levva S. et al, (2021), Forum of Clinical Oncology, 12, 82 - 104